MetaVia (MTVA) 10-Q 2024 Q2 Quarterly report

Exhibit 31.1

Certification of Chief Executive Officer

pursuant to Rule 13a-14(a) or Rule 15d-14(a)

I, Hyung Heon Kim, certify that:

(1) I have reviewed this quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 of NeuroBo Pharmaceuticals, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omitto state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by thisreport;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairlypresentinallmaterialrespectsthe financialcondition, resultsofoperationsandcashflowsoftheregistrantas of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer(s) and Iareresponsibleforestablishingandmaintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is beingprepared;

(b) designed such internal control over financial reporting, or caused such internal control over financialreportingtobedesignedunderoursupervision,toprovidereasonableassurance regardingthereliabilityof financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accountingprinciples;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annualreport)thathasmateriallyaffected,orisreasonablylikelyto materiallyaffect,theregistrant’sinternalcontrol over financial reporting;and

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internalcontroloverfinancialreporting,totheregistrant’sauditorsandtheauditcommitteeoftheregistrant’sboard of directors (or persons performing the equivalentfunctions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal controlover financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;and

(b) any fraud, whether or not material, that involves management or other employees who havea significant role in the registrant’s internal control over financialreporting.

Date: August 14, 2024	/s/ Hyung Heon Kim
	President and Chief Executive Officer
	(Principal Executive Officer)